SOVAPREVIR TABLETS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Mar 13, 2014
filing date -
Mar 15, 2013
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), copovidone (PVP-VA), a copolymer of methacrylic acid and ethyl acrylate, or any combination of the foregoing, wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully